AptaPharma Funding: How Much Did They Raise & Key Investors

How Much Did AptaPharma Raise?
Funding & Key Investors

AptaPharma, a specialized Contract Development and Manufacturing Organization (CDMO), has successfully secured significant capital to bolster its operational capacity. The firm has reached a cumulative financing milestone of $509K, underscored by a recent strategic investment of $359K. This influx of liquidity positions the Pennsauken-based entity to further refine its proprietary SLP technology and expand its footprint within the competitive pharmaceutical manufacturing landscape.

The company's growth trajectory is marked by a series of debt-based financing rounds, beginning with an initial capital injection in April 2020, followed by a substantial expansion of its balance sheet in February 2021. This progression reflects a deliberate strategy to scale infrastructure while maintaining rigorous cGMP compliance standards for its complex oral and liquid formulation services.

What is AptaPharma?

AptaPharma

Manufacturing

Pharmaceuticals

Business Services

AptaPharma operates as a critical partner for pharmaceutical enterprises, providing end-to-end solutions that span from early-stage research and development to full-scale commercial manufacturing. By leveraging its proprietary SLP technology, the company addresses the technical challenges inherent in complex drug delivery systems. Its market position is defined by a commitment to high-precision formulation, serving as an essential link in the pharmaceutical supply chain for clients requiring specialized manufacturing expertise and regulatory adherence.

How much funding has AptaPharma raised?

AptaPharma has raised a total of $509K across 2 funding rounds:

2020

Debt

$150K

2021

Debt

$359K

Debt (2020): $150K with participation from PPP

Debt (2021): $359K led by PPP

Key Investors in AptaPharma

PPP

Public-Private Partnership

What's next for AptaPharma?

With the recent infusion of capital, AptaPharma is poised to accelerate its strategic objectives, likely focusing on the enhancement of its manufacturing facilities and the broader adoption of its SLP technology. As the CDMO sector continues to experience consolidation and increased demand for specialized formulation capabilities, AptaPharma is well-positioned to capture additional market share. Future growth will likely hinge on the company's ability to scale its operational throughput while maintaining the stringent quality controls that define its competitive advantage in the pharmaceutical services industry.

See full AptaPharma company page

See More Financial Insights